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Gastrointestinal/Pancreatic Hormone Concentrations in the Portal 
Venous System of Nine Patients With Organic Hyperinsulinism 
B. Glaser, G. Valtysson, S. S. Fajans, A. I. Vinik, K. Cho, and N. Thompson 
Percutaneous transhepatic sampling of blood in the portal venous system (TPVS) was used to; (1) localize hormone 
secreting tumors and help in differentiating tumors from diffuse disease (nesideoblastosis and hyperplasia with 
adenomata) in 9 patients with fasting hypoglycemia and hyperinsulinism, and (2) study the concentration and distribution 
of the immunoreactive peptides: insulin (IRI), gastrin (IG), glucagon (IRG). pancreatic polypeptide (hPP). and somatostatin 
(SRIF-LI), in the venous drainage of the uninvolved portion of the pancreas and GI tract. Localized elevations of IRl (64-920 
pU/ml) predicted tumor localization in 6 patients with single tumors that were not demonstrable angiographically. In one 
patient with nesideoblastosis and another with islet cell hyperplasia with adenoma. elevated IRI concentrations at multiple 
locations suggested a diffuse or multicentric process. Elevations of SRIF-LI in the same region as IRI elevations in one 
patient and of IRG in another patient suggested that these tumor produced two hormones. Some problems in the 
interpretation of portal venous insulin concentrations are discussed. The locations of maximum portal venous system 
plasma concentrations and portal-arterial gradients (mean + SE pg/ml) in five patients with small single insulinomas were: 
IG. gastrocolic trunk (126 +_ 27.46 f 22); IRG, proximal splenic vein (130 +- 30,47 ? 13) and gastrocolic trunk (131 + 23, 
60 +_ 13); hPP. portal vein (164 + 48, 49 + 22); SRIF-LI, superior mesenteric vein (186 + 50. 57 ? 20) and gastrocolic 
trunk (178 + 59, 55 + 21). It is concluded; (1) TPVS can be used successfully to localize single insulin-secreting tumors of 
the pancreas and to help distinguish them from diffuse disease but problems in such differentiation do occur, (2) circulating 
SRIF-LI and IRG are derived from both the pancreas and the gut, IG predominantly from the proximal gut and hPP from the 
head of the pancreas, and (3) The data provide new information for the interpretation of portal insulin concentrations in 
patients with organic hyperinsulinism and of hormone concentrations for localization of peptide-producing tumors of the 
pancreas other than insulinomas. 
H ORMONE-SECRETING tumors of the gastro- intestinal tract occur predominantly in the 
pancreas, and rarely in and around the duodenum and 
stomach. When these tumors are small, localization by 
angiography’.‘.’ may fail. Abdominal ultrasound4 and 
computed tomography (CT) have proved of limited 
value. Insulinomas, for example, are not localized by 
these methods in 344 of cases.’ Ingemansson, et al.’ 
tirst demonstrated the feasibility of percutaneous 
transhepatic sampling of blood from the portal venous 
system (TPVS) with identification of high IRI concen- 
trations in the venous effluent at the site of a tumor. 
This technique has been employed by several groups in 
the successful localization of insulinoma&” and there 
have been three cases reported from the United 
States.‘.’ 
Aside from insulinomas, tumors secreting gastrin,” 
glucagon, ‘* somatostatin,” ” human pancreatic poly- 
peptide (hPP),‘O vasoactive intestinal polypeptide 
(VIP),“,” mixed endocrine tumors,” and diffuse islet 
cell adenomatosisZ4 have all been described as produc- 
ing clinical syndromes. Gastrinomas,‘5.26 glucagono- 
mas” and islet cell hyperplasia*” have been localized 
by hormone concentrations in the portal venous 
effluent. There has been no report of the concentration 
of hormone levels in the venous effluent of somatosta- 
tin-secreting or mixed endocrine tumors. 
The various hormone-secreting cells are not evenly 
distributed throughout the pancreas.29~30.3’ This non- 
homogeneity of hormone content, if reflected in portal 
venous hormone concentrations, may complicate inter- 
pretation of data obtained in patients with gastrin. 
glucagon, somatostatin or pancreatic polypeptide 
secreting tumors. For this reason it is important to 
establish the “normal” pattern of hormone secretion 
into the gut and pancreatic venous drainage. 
We report here localization of tumors in five 
patients with single insulinomas; recognition of multi- 
centric or diffuse disease in one patient with nesideo- 
blastosis and one with islet hyperplasia and adenoma; 
and the diagnosis of a mixed insulinoma/somatosta- 
tinoma and insulinoma/glucagonoma. We have also 
established the profile of hormone concentrations of 
gastrin, “pancreatic” glucagon, hPP and somatosta- 
tin-like immunoreactivity (SRIF-LI) in the portal 
venous system, and the portal-systemic concentration 
gradients of these peptides in humans. 
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Table 1. Clinical Details of 9 Patients with Organic Hyperinsulinism 
- 
Prolonged Fast 
Duration of GltK0S.e Fasting 
Height Wetght Symptoms Hours to Nadir IRI PVXl.Vllll operarwe 
Patient Age Sex (Inches) (pounds) w Hypoglycemia* (ma%) @Ulmt) I/G? AllGS I%,§ Findings// 
A. EV 26 M 68 214 2.5 16.5 42 22 0.5 236 62 1 
B. DS 40 F 65 179 7 15 42 36 0.86 300 22 1 
C. NH 33 M 72 189 10 12 41 14 0.34 127 53 1 
D. RS 21 F 63 148 1 17.5 39 63 1.66 788 31 1 
E. A0 60 M 70 191 2 21 44 30 0.69 214 44 1 
F. ASa 30 M 68 211 2 18 41 53 1.29 481 67 1 
G. AW 20 M 63 165 19 20.5 40 23 0.58 233 23 2 
lsee below) 
H. AS 58 F 66 233 1 45 43 17 0.4 131 31 3 
I. SP 23 F 60 103 10 66 37 38 1.03 540 66 1 
1 = single adenoma. 
2 = nesideoblastosis. 
3 = macroadenoma + islet hyperplasia. 
None of the patients had a personal or family history of multiple endocrine neoplasia. 
AW had symptoms from age 1- 17 yr which were thought to be due to a convulsive disorder; biochemical hypoglycemia was recognized for the first 
time at age 17 yr. There was some change in symptomatology between ages 17-20 yr; it was entertained that he may have developed fasting 
hypoglycemia during this period of time. Because the confusing nature of the history and intermittent hyperinsulinism. the patient was referred for 
differential diagnosis and treatment. 
‘Symptomatic hypoglycemia. 
Tl/G = Insulin @J/ml/Glucose mg/dl ml = <0.3). 
fAI/G = Amended I/G = insulin mg/dl/Glucose mg/dl - 30 ml 5 50) (32). 
SNormal Proinsulin ~22%. 
//Operative fmdings. 
MATERIALS AND METHODS 
Patients 
The clinical details of the 9 patients are given in Table 1. All had 
symptomatic hypoglycemia due to organic hyperinsulinism diag- 
nosed before transhepatic venous sampling by; (I) the presence of 
inappropriately high plasma insulin concentrations for the prevail- 
ing glucose concentration. including an abnormal plasma insulin/ 
glucose ratio or “amended ratio”? and (2) a plasma proinsulin 
content of 222% of total insulin immunoreactivity in the fasting 
state of all patients except D.S. ” All underwent pancreatic angi- 
ography which included utilization of subselective catheterization 
technique and pharmacoangiography. Additional subtraction and 
magnification techniques were used to enhance tumor visibility. In 
addition to selective celiac and superior mesenteric angiography, 
superselective injections of splenic, gastroduodenal, dorsal pancreat- 
ic, pancreatica magna and inferior pancreaticoduodenal arteries 
were necessary to adequately visualize the entire intrapancreatic 
arterial system and produce a pancreatic parenchymal stain. A 
tumor was demonstrable angiographically in 2 patients (AS. & 
S.P.) 
Catheterization Procedure 
Before transhepatic portal vein catheterization, the venous phase 
of the celiac and superior mesenteric angiograms were reviewed to 
locate and establish the patency of the portal vein. Each subject 
received heavy sedation and analgesia with demerol, Valium and 
chlorpromazine. Under local anesthesia, a I9-gauge Teflon catheter 
was introduced in the mid-axillary line and with the patient holding 
his breath the catheter was advanced in the horizontal plane towards 
the hepatic hilum. The placement of the tip of the catheter in a 
portal venous radicle was confirmed by radio-opaque dye injection. 
The catheter was then advanced into portal, splenic and superior 
mesenteric veins over a curved guide wire. Portograms were 
obtained with injection of contrast medium into the distal splenic 
and superior mesenteric veins, respectively. Using these portograms 
to identify sites along the venous drainage (Fig. I), blood samples 
were obtained along the superior mesenteric, splenic and portal 
veins at 1.5-2 cm intervals, Additional samples were obtained from 
the dorsal pancreatic, gastrocolic, coronary, and superior pancreati- 
co-duodenal veins whenever possible. A catheter was also placed in 
the celiac artery via a percutaneous transfemoral approach and 
arterial blood samples were collected simultaneously with each 
venous sample. After the procedure was completed, the transhepatic 
venous catheter was withdrawn to near the hepatic capsule and the 
catheter track was filled with one or two pieces of Gelfoam to 
prevent hemorrhage or leakage of bile. 
In all patients except one (N.H.), glucose concentrations 
remained stable throughout the procedure. In this patient, because 
of the presence of early morning hypoglycemia despite adequate 
night time feeding, a constant intravenous infusion of glucose was 
maintained during the procedure. Plasma glucose concentrations 
were elevated in this patient throughout the procedure. 
Blood Sampling and Storage 
Each blood sample (7-8 ml) was immediately aliquoted into two 
heparin-coated tubes, one containing Trasylol (Aprotinin, Mobay) 
1000 KIU/ml whole blood. Both tubes were gently mixed and 
immediately placed on ice. Plasma was separated in a refrigerated 
centrifuge within 60 minutes. The plasma containing Trasylol was 
aliquoted into two plastic tubes for SRIF-LI assay while the 
remaining plasma was aliquoted into three tubes for remaining 
hormone and glucose assays. All samples were frozen for later assay. 
Care was taken to avoid thawing and refreezing of samples before 
glucagon and SRIF-LI determinations. 
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Glucagon 
Fig. 1. Injections of splenic and superior mesenteric veins 
with superimposed numbers showing location of blood sampling. 
HORMONE ASSAYS 
Insulin 
lmmunoreactive insulin was measured by a double-antibody RIA 
which detects total insulin in plasma.” The least detection limit was 
0. IS pU/tube, the intraassay variation was 3.2%. The mean 2 SE 
concentration of insulin in peripheral venous plasma from fasting 
healthy nonobese subjects was 10.9 i I.4 pU/ml. 
Ga.vtrin 
lmmunoreactive gastrins were measured by RIA using ion 
exchange resin to separate the bound from free-labeled peptide.” 
The antisera (G2 Cape Town, South Africa) recognizes all forms of 
gastrin. Synthetic heptadecapeptide 1%Leu gastrin was used for 
labeling with ‘I51 and l5-Met-gastrin as standard. The least detec- 
tion limit was 0.16 pgjtube, the intraassay variation was 4%. The 
mean + SE concentration of gastrin in peripheral venous plasma of 
fasting healthy subjects was 45 I 9 pg/ml. 
Plasma levels of “pancreatic” glucagon (IRG) were measured 
using a double antibody RIA.j6 The antiserum. G9-I (Ann Arbor. 
Michigan) used in the assay detects the C-terminal region of the 
glucagon molecule and has negligible (2%-5%) cross-reactivity with 
intestinal glucagon-like material (GLl). It does, however, detect 
glucagon of varying molecular weights. The mean ? SE plasma 
concentration of glucagon in fasting young adults was 64 ? 8 pg/ml. 
The least detection limit was 3.4 pg/tube. the intraassay variation 
was 4. I % 
Pancreatic Polypeptide 
Human pancreatic polypeptide was measured by double antibody 
RlA3’ using ‘“51-labeled bPP as tracer (Eli Lilly Co. lot no. 615 
D63-18%9), antiserum to hPP (Eli Lilly lot no. 615-1054B-248-19) 
and hPP (Eli Lilly & Co. lot no. 6 15-l 054B-200) as standard. The 
least detection limit was 2.5 pg/tube, the intraassay variation was 
12%~. The levels of peripheral venous plasma hPP (mean + SD) in 
fasting healthy subjects by decades. 3-7 (263 subjects) were: 54 + 
28, II5 + 98, 165 k 159, I81 2 166,207 -r 129 pg/ml. 
Somatostatin 
lmmunoreactive somatostatin (SRIF-11) was measured by RIA 
using charcoal to separate the bound and free-labeled hormone.” 
The antiserum (I 374 Cape Town, South Africa) recognizes the 
C-terminal 6-l I aminoacid region. Tyr’-SRIF (courtesy of J. 
Rivier, Salk Institute, LaJolla, California) was labeled with “‘1 to a 
specific activity of 1000 rCi/wg and repurified by cation exchange 
chromatography using Whatman CM,, cellulose and an ammonium 
acetate gradient of 0.05-500 mM. Plasma samples were not 
extracted. The assay was carried out at pH 5.3 in 50 mM ammo- 
nium acetate buffer containing 0.05% EDTA. Under these condi- 
tions, incubation of tracer in plasma for 48 hours resulted in less 
than 2% damage. adsorption to charcoal was 92% and nonspecific 
adsorption to plasma proteins was 2%. SRIF-LI added to plasma 
was completely recovered and serial dilutions of plasma were paral- 
lel to the synthetic standard. The least detection limit was 1.75 
pg/tube, the intraassay variation was 12%. SRIF-LI concentrations 
in unextracted peripheral venous plasma of fasted healthy subjects 
ranged between 50-300 pg/ml. 
Plasma glucose was measured by the procedure of Worthington 
Biochemical Company based on the coupled-enzyme method of 
Slein.” using hexokinase and glucose-h-phosphate dehydrogenase. 
with modifications by Bondar and Mead.JO 
RESULTS 
In 6 of the 9 patients studied, pancreatic angiogra- 
phy, abdominal CT scan and ultrasound failed to 
identify a tumor where a single tumor was later found 
at operation; one in the head, three in the neck, one in 
the body, and one in the tail of the pancreas. All six of 
these tumors were localized by the maximum hormone 
level in the portal venous system (Table 2A-E). 
Figure 2A-E is a schematic representation of the sites 
of each tumor and the concentrations of insulin in the 
portal venous system in 5 of these patients. A sixth 
patient, ASa., had a single tumor in the neck of the 
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Head 2x1 64 25 
Neck 0.8 x 1.0 941 43 
Body 1x1 690 22 
Neck 2.5 x 2 240 69 
Tail 2x3 292 41 
Neck 1.9 x 1.7 863 80 
Head 7x5 73 21 
452 43 
140 9 
39 20.1 _+ 1 
898 36 i 2.5 
668 37 + 5 
171 55 i 1 
251 30.6 ‘- 2.7 
783 61 + 4.2 
52 16.5 + 1 
409 36.6 
137 6.3 
22 i 1.1 -2 
44 * 1.5 -8 
29 & 1 +6§ 
63 * 1.4 -8 
38 i 2.5 -7 
69 + 3.6 -8.2 
18 ? 1 ~ 1.5 
40 -3.8 
7.4 -2.2 
‘PVS = portal venous system. 
tPortal venous system - simultaneous celiac arterial insulin concentration. 
ttAbdominal angiogram, CAT and ultrasound negative. 
§This patient received glucose during the procedure which may explain the positive IRI gradient. 
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Fig. 2. Schematic representations of pancreas and portal- 
venous system in 5 patients with localized insulin-producing 
tumors not demonstrated by angiograph. Plasma insulin levels are 
shown throughout the portal system along with location of the 
tumor found at surgery. The apparent inconsistent findings in Fig. 
2E (AS.) are explained partially in Fig. 6. 
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pancreas (Fig. 3). Elevated glucagon concentrations in 
the portal venous system (Fig. 3B) adjacent to the 
elevated insulin concentrations suggested glucagon as 
well as insulin production by the tumor. The maxi- 
mum IRI concentrations ranged from 64-941 gU/ml 
with a mean k SE of 452 f 140 &/ml (Table 2). The 
mean + SE of insulin concentrations in samples drawn 
simultaneously from the celiac artery was 43 f 9 
pU/ml and that in the veins draining the uninvolved 
pancreas was 36.6 + 6.3 &/ml. The gradient (tumor 
site- simultaneous arterial) ranged from 39-898 PU / 
ml with a mean k SE of 409 4 137 pU/ml. 
In a seventh patient (A.W., Table IG) also with 
negative preoperative angiography elevated insulin 
concentrations were found in the distal and midsplenic 
vein, proximal pancreatic vein (highest level) and the 
portal vein, suggesting multiple areas of insulin hyper- 
secretion (Fig. 4A). A tumor was not found at opera- 
tion and a 95%) pancreatectomy performed. Extra-islet 
endocrine cells which stained immunochemically for 
insulin were seen associated with pancreatic ducts, 
confirming the diagnosis of nesideoblastosis. Extra- 
A INSULIN 
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SUPERIOR MESENTERIC v. 
Fig. 3. Schematic representation of pancreas and portal 
venous system in a 30-yr-old male lA.Sa.1 with fasting hypogly- 
cemia. Elevated concentrations of both IRI (A) and IRG fB) from 
the venous drainage of the neck of the pancreas suggests that the 
tumor produced both hormones. 
b 2 
SUPERIOR MESENTERIC v. 
B A.S. 58,Fwnak 
SUPERIOR MESENTERIC V. 
Fig. 4. Schematic representation of the pancreas and portal- 
venous system in 2 patients with diffuse or multifocal excessive 
insulin production IAl nesideoblastosis (B) islet hyperplasia with 
macroedenoma. Plasma insulin levels are shown throughout the 
portal system. 
islet insulin-containing ductal cells and large, irregu- 
larly-shaped islet cells as well as normal-appearing 
islets were particularly frequent in the head of the 
pancreas corroborating the findings at TPVS that the 
most marked elevation of IRI was in the venous 
drainage of the head of the pancreas. 
In the 2 remaining patients angiography did demon- 
strate the presence of a tumor. Patient A.S. (Fig. 4B) 
who had an angiographically demonstrated tumor in 
the tail of the pancreas had on TPVS elevated IRI 
concentrations in the midsplenic vein, inferior mesen- 
teric vein (IMV), posterior superior pancreaticoduo- 
denal (PSPDV). and the dorsal pancreatic vein. 
suggestive of a multicentric or diffuse process. This 
patient had undergone pancreatic surgery I yr earlier 
for hyperinsulinism with the enucleation of a single 
adenoma from the tail of the pancreas. At surgery this 
time, only the angiographically demonstrable tumor 
was palpable and frozen section examination of adja- 
cent pancreas was “normal.” Because of the demon- 
stration by TPVS of non-localized disease, enucleation 
of the tumor was not attempted and a distal 2/3 
pancreatectomy was done. Histologic examination 
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confirmed the presence of a single, lobulated adenoma 
and demonstrated associated diffuse islet cell hyper- 
plasia. 
Patient S.P., who presented with fasting hypogly- 
cemia and hyperinsulinemia, had a large tumor (32 g) 
of the head of the pancreas which was easily demon- 
strated angiographically. The highest insulin concen- 
trations were found in the proximal superior mesen- 
teric vein at or near the confluence with the splenic 
vein (Fig. 5A). High values of SRI F-LI were found in 
a distribution similar to that of insulin (Fig. 5B) 
suggesting that the tumor produced SRIF-LI as well. 
None of the 9 patients has had recurrence of symp- 
toms of organic hyperinsulinism. One patient (A.W.) 
is an insulin-requiring diabetic as a result of extensive 
resection of the pancreas. 
In the six cases with small single adenomata, 
elevated concentrations of IRI were not always found 
exclusively in close proximity to the tumor. The high- 
est concentration of insulin was found in the distal 
splenic vein in patient (A.B.) with a tumor in the tail 
of the pancreas (Fig. 2E). Elevated concentrations 
A INSULIN S.t? 23, Female 
-43 
SUPERIOR MESENTERIC 
ARTERiAL 18 f 1.0 
PERIPHERAL 
MNOlB 19 t 9.3 
M*on t SE 
v 
B SRIF-LI 
SUPERIOR MESENTERIC v. 
Fig. 5. Schematic representation of pancreas and portel- 
venous system in a 23-yr-old female ISP) with e IO-yr history of 
symptoms of hypoglycemia. Angiogrephy had located a large 
hypervasculer tumor in head of the pancreas. Elevated levels of 
both insulin end SRIF-LI from the venous drainage of the head of 
the pancreas suggests that the tumor produced both hormones. 
Fig. 6. Venous drainage into the gastroepiploic vein from an 
insulinoma located in the tail of the pancreas explaining the 
finding of elevated level (I 19 AU/ml) of insulin et the unexpected 
location remote from the tumor site (Fig. 2E). 
were also found in the proximal splenic vein and in the 
gastrocolic trunk. A venous communication between 
the tail of the pancreas and the superior mesenteric 
vein via the gastroepiploic veins was visualized at 
surgery (Fig. 6). Patient N.H. had a tumor in the body 
of the pancreas. The highest concentration of insulin 
was found just distal to the tumor location in the 
splenic vein. However, there was also a lesser elevation 
proximal to this site. Direct drainage of a tumor 
located in the neck of the pancreas into the portal vein 
could be demonstrated at surgery in patient R.S. (Fig. 
7). Duplicate sampling from the same site (Table 3) in 
the portal venous system at different times occasion- 
ally gave differing IRI concentrations. 
R.S. 21, Female 
Fig. 7. Demonstration et operation of e tumor in the neck of 
the pancreas with direct venous communication into the proximal 
portal vein. The high insulin concentrations in the proximal portal 
vein (R.S. Fig. 2D) may be misinterpreted as coming from a tumor 
in the heed of the pancreas. 
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Table 3. Examples of Differences in Portal Venous IRI 
Concentrations with Non-Simultaneous Sampling 


















Sample 1 62 152 40 91 30 
Sample 2 79 231 73 119 55 
In the 5 patients with single insulinomas, the mean 
concentrations of IG, IRG, hPP and SRIF-LI in the 
portal venous system are given in Table 4 along with 
the portal/systemic gradients. Patients A.W. and A.S. 
were excluded from this analysis because of their 
diffuse disease process which may be associated with 
other islet hormone abnormalities. Patient S.P. and 
ASa. were excluded because their tumors produced 
more than one hormone, a situation that may affect 
the secretory patterns of other hormones. The highest 
concentration and significant gradient of gastrin was 
found in the gastrocolic trunk; hPP gradient was 
greatest in the proximal-portal vein; SRIF-LI gradient 
was greatest in the superior-mesenteric vein and 
gastroepiploic vein; IRG concentrations were similar 
at all locations with positive gradients throughout the 
portal venous system. 
DISCUSSION 
We have carried out transhepatic portal venous 
sampling to; ( I ) localize insulin-producing tumors and 
to help in differentiating single tumors from diffuse 
disease (nesideoblastosis and hyperplasia with adeno- 
ma) and (2) determine concentrations of other gut/ 
pancreatic hormones in the portal venous system. 
We have studied 6 patients with small single adeno- 
mas that were not angiographically demonstrable and 
have confirmed the findings of others6-” that even 
small tumors (<I cm) can be localized preoperatively 
using the technique of TPVS. In 5 of these 6 patients, 
preoperative localization by TPVS was helpful to the 
surgeon in directing him to the tumor site since it was 
not easily palpable at initial exploration. 
Two patients with diffuse pancreatic disease were 
also studied. One, AS., had a single lobulated tumor 
demonstrated angiographically preoperatively, how- 
ever, the history of prior removal of another ademona 
suggested the presence of multiple adenomatosis. At 
surgery, a single tumor was found, associated with 
diffuse hyperplasia. The other patient, A.W., had in 
retrospect a history suggestive of hypoglycemia dating 
from one year of age, however, biochemical hypogly- 
cemia was not recognized until age 17 yr (Table I). 
Nesideoblastosis was found at operation. Both of these 
patients had multiple areas of elevated IRI concentra- 
tions suggesting that: (I) both these processes are 
non-homogeneous, and (2) TPVS cannot differentiate 
nesideoblastosis from hyperplasia with adenoma. 
Multifocal, nonhomogeneous secretion of insulin was 
found in a patient with hyperplasia without adeno- 
mata by Ingemansson.2x Thus, nesideoblastosis and 
hyperplasia with and without adenomata cannot be 
distinguished by the hormonal profile in TPVS. 
The interpretation of data obtained during these 
and similar studies requires an appreciation of the 
complexity and variability of the venous drainage of 
the pancreas and proximal gut. We have demonstrated 
that a tumor in the tail of the pancreas can drain into 
the gastroepiploic vein (A.B.) resulting in high 
hormone levels remote from the actual tumor site (Fig. 
6). The high insulin concentration noted near the 
confluence of the splenic and superior mesenteric veins 
in the same patient (Fig. 2E) may be related to tumor 
drainage through the short gastric veins into the coro- 
nary vein which enters at that point. The findings of a 
moderately elevated concentration of insulin in the 
splenic vein proximal to the tumor in patient N.H. 
may relate to variabilities of venous admixture, or 
catheter placement. Such findings may present diffi- 
culties in differentiation of patients with single tumors 
from those with diffuse disease who have elevated 
concentrations found at multiple remote sites such as 
patient A.S. whose elevated IRI concentrations in the 
PSPDV is not compatible with collateral drainage 
from a tumor in the body or tail of the pancreas. 
A tumor of the head of the pancreas (E.V.) could be 
identified by high insulin levels in the area of drainage 
into the superior pancreaticoduodenal vein, while one 
in the neck of the pancreas (R.S.) drained into the 
proximal portal vein close to the junction of the 
superior mesenteric and splenic veins. A tumor of the 
body of the pancreas (N.H.) drained into the mid- 
splenic vein. A maximum insulin concentration as low 
as 64 wU/ml or a tumor site-arterial gradient of 39 
&l/ml may be sufficient to localize a tumor. Values as 
low as 41 9 and 62 pU/mlx have been reported. 
Repeated sampling at the same location at different 
times can yield variable hormone concentrations. This 
variability may be due to a minor error in estimating 
catheter location, laminar Row of blood within major 
veins, or pulsatile hormone secretion. In none of our 
cases did this problem result in error of localization 
however. multiple site samplings and repetitive 
samplings at different times may help in identifying 
spuriously elevated or suppressed levels. 
Two patients had evidence on TPVS of multiple 
hormone production by their tumors. The normal 
peripheral glucagon concentrations, even though there 
was excessive glucagon output by the tumor in patient 
A.Sa., explain the absence of the usual stigmata of the 
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glucagonoma syndrome such as migratory necrolytic 
erythema. The other patient (S.P.) had a large tumor, 
but relatively low fasting IRI concentrations. The 
finding of excessive SRIF secretion from the tumor 
may explain why IRI concentrations were not higher 
and hypoglycemic symptoms were not more severe. 
That there were none of the features of somatostatin 
excess-steatorrhea, achlorhydria or gall bladder 
disease,‘3m’9 may be related to the relatively low (400 
pg/ml) circulating SRIF concentrations. In patients 
with symptomatic somatostatinomas, peripheral ve- 
nous concentrations were generally > 1000 pg/ml.‘3m’9 
The use of TPVS for the evaluation of patients with 
organic hyperinsulinism is indicated only after a defin- 
itive diagnosis has been made using the appropriate 
clinical and laboratory tests, and only in those patients 
where a tumor has not been located angiographically 
or when a diffuse process is suspected. Patients with 
recurrent hypoglycemia after removal of an insulino- 
ma, patients with multiple endocrine neoplasia Type I 
(MEN-l) or with a family history of MEN-I often 
have diffuse pancreatic disease and even if a single 
adenoma is demonstrated angiographically, TPVS is 
indicated before operation. The use of TPVS in 
patients with a clinical presentation of a single insuli- 
noma demonstrable angiographically is not justified at 
this time as the procedure is not innocuous. although 
we encountered no major complications in the nine 
patients studied. 
Most of these patients complained of severe right 
flank and epigastric pain during the procedure despite 
narcotic analgesia and sedation. This pain persisted 
for l-2 days, but rarely required further analgesia 
after the first 4-6 hr. Seven of the nine patients were 
ambulatory and could be discharged 24 hr after the 
procedure was completed, though two remained hospi- 
talized for further testing. One patient (R.S.) had a 
decrease in hematocrit following the procedure, proba- 
bly related to bleeding into the thigh at the site of 
arterial puncture, but blood loss from the transhepatic 
procedure cannot be entirely ruled out since stools, 
while grossly normal, were positive for occult blood. 
Another patient (A.W.) had flank tenderness, rebound 
tenderness, and an increase in abdominal girth, which 
resolved spontaneously after 72 hr. 
lmmunohistochemical studies have determined that 
gut/pancreatic hormones are not distributed evenly 
throughout the entire pancreas. By studying the 
concentrations of hormones other than insulin in the 
gut/pancreatic venous effluent of patients with single 
small insulinomas we have been able to obtain an 
estimation of the maximum concentrations and 
portal-systemic gradients of these hormones in the 
unaffected pancreas, and have also found this distribu- 
tion to be non-homogeneous for gastrin, hPP and 
SRIF-LI, providing functional confirmation of the 
previous anatomical findings. 
The maximum concentration of gastrin in the 
gastrocolic trunk is compatible with its origin from the 
gastric antrum and the absence of a significant 
gradient between the concentrations in the pancreatic 
venous effluent and the systemic circulation supports 
the observation that there are no gastrin cells in the 
adult human pancreas and that heptadecapeptide 
gastrin is not inactivated by passage through the 
liver.4”4’ 
The glucagon concentrations measured with this 
antiserum reflect “pancreatic” IRG. There is only 
2%5% cross-reactivity with GLI. The levels in the 
peripheral venous system are lower than those 
reported in healthy subjects using Unger’s 30 K anti- 
serum and the portal vein/arterial gradient of 31% 
(Table 4) is acceptable for the known hepatic extrac- 
tion of glucagon.43 The positive gradients found in the 
superior mesenteric and gastrocolic trunk suggest 
secretion of a “pancreatic” type glucagon produced by 
the gut in humans and is in keeping with persistence of 
IRG in the circulation after total pancreatectomy in 
man.44 
The hPP concentrations in the portal vein were 30% 
greater than in the peripheral circulation. A positive 
portal-peripheral venous concentration-difference in- 
dicating hepatic extraction of PP has been demon- 
strated,45,46.47 but not confirmed.4R The highly selective 
elevation of hPP levels only in the distal portal vein, 
could account for the failure48 to find a gradient, since 
Table 4. Mean (+ SE) Hormone Concentrations and 
Portal-Systemic Arterial Gradients in 5 Patients With 
Single Insulinomas’ 
Gastrm Glucagon hPP SRIF-LI 
w/ml w/ml w/ml w/ml 
Splenic V. 82 * 12 130+ 30 124? 35 IOS? 20 
V-At 4*3 $47&13 -I*9 2+5 
Sup. Mes. V. 83 ? 13 114 ? 19 96 + 20 186 + 50 
V-A -1*2 $25 * 12 -6 t8 $57 + 20 
Portal V. 85?13 123+25 164t48 126*21 
V-A 5+2 $38? 18 $49 i 22 2.4 2 7 
Gastrocolic trunk 126? 27 131 ?23 144k 57 178 + 59 
V-A $46i22 $602 13 34+30 $55+21 
Celiac Arterial go+ 13 94+ 19 95 ‘- 31 125 r 26 
Peripheral 
venous 765 12 84 * 19 114 f 26 126 f 25 
Portal/Systemic 
Gradient (%I§ 6 311 30. 2 
*Patients A-E Table I. 
ttvlean ? SE of plasma hormone concentration gradient between vein 
indicated W) and simultaneous celiac arterial (A) sample. 
SSignificant p 5 0.05. 
SPortal Vein Gradient divided by mean portal vein concentration x 
100%. 
HORMONE CONCENTRATIONS IN PORTAL SYSTEM 
samples may have been taken at too proximal a site. 
The higher levels in the portal vein, close to the liver, 
adjacent to the posterior superior pancreaticoduodenal 
vein are in keeping with the anatomic localization of 
most of the PP cells in a separate lobe in the head of 
the pancreas.‘q.3” 
The fasting SRIF-Ll concentrations in the periph- 
eral vein and celiac artery are similar to those reported 
in healthy subjects3’ when unextracted plasma is used, 
but may be higher than levels found in extracted 
plasma. The greatest concentrations is the gastrocolic 
trunk and superior mesenteric veins suggest that in 
man most of the SRIF-LI secreted into the portal 
venous system derives from the proximal small gut 
corresponding with the greatest tissue levels found by 
extraction of the gut and pancreas in dog and man.” 
These data will be necessary in the interpretation of 
future studies done for localization of tumors produc- 
ing these hormones. 
In our studies we have obtained celiac artery and/or 
peripheral venous samples simultaneously with portal 
samples. While these values were not needed in any of 
our cases to adequately localize the tumors, calcu- 
lating portal-systemic gradients of SRIF-LI, gluca- 
gon, and hPP can be expected to add to the accuracy 
of localizing maximum concentrations and gradients 
by avoiding apparent differences due to rapid oscilla- 
tions of hormone levels. 
In summary. we have localized by TPVS small 
angiographically-negative insulinomas in 6 patients. 
Some problems in interpretations of portal venous 
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insulin concentrations are discussed. We have demon- 
strated the non-homogeneous pattern of IRI secretion 
in a patient with nesideoblastosis and one with islet 
hyperplasia and adenoma, making it impossible to 
distinguish these two entities by this procedure. We 
have demonstrated glucagon production by an insuli- 
noma in a patient with normal peripheral plasma 
concentration of glucagon and SRIF production by a 
large insulinoma in a patient with normal peripheral 
plasma SRIF concentrations. The procedure appears 
to be relatively safe albeit painful, and can be recom- 
mended for those patients with proven organic hyper- 
insulinism but negative pancreatic angiograms or 
those with recurrent hypoglycemia due to multiple 
tumors or MEN-I. We have also delineated some of 
the complexities of the pancreatic venous drainage and 
provided new information on the concentrations and 
gradients of IRG, hPP, SRIF-LI and gastrin in the 
portal venous system in man, which may be helpful in 
the interpretation of future studies. 
NOTE ADDED IN PROOF 
Since submission of this manuscript we have localized by TPVS 
two more single insulinomas which were not demonstrable angio- 
graphically, each located in the uncinate process of the pancreas, 
Concentrations of insulin were highest in the superior mesenteric 
vein; in one patient opposite the entry of the gastrocolic trunk and 
the posterior inferior pancreatico-duodenal vein and in the other 
patient half way between the entry of the gastrocolic trunk and the 
confluence of the superior mesenteric vein and splenic vein. In both 
patients preoperative localization of TPVS was most helpful to the 
surgeon as the tumors became palpable only after mobilization and 
dissection of the uncinate process, 
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